Opening book details…
About this book
Conversion of a PROTAC Mutant Huntingtin Degrader into Small-Molecule Hydrophobic Tags Focusing on Drug-like Properties by Keigo Hirai, Hiroko Yamashita, Shusuke Tomoshige, Yugo Mishima, Tatsuya Niwa, Kenji Ohgane, Mayumi Ishii, Kayoko Kanamitsu, Yui Ikemi, Shinsaku Nakagawa, Hideki Taguchi, Shinichi Sato, Yuichi Hashimoto & Minoru Ishikawa is a book available to read on EtoBox.
- Author
- Keigo Hirai, Hiroko Yamashita, Shusuke Tomoshige, Yugo Mishima, Tatsuya Niwa, Kenji Ohgane, Mayumi Ishii, Kayoko Kanamitsu, Yui Ikemi, Shinsaku Nakagawa, Hideki Taguchi, Shinichi Sato, Yuichi Hashimoto & Minoru Ishikawa
- Published
- 2022
- Language
- EN
More by Keigo Hirai, Hiroko Yamashita, Shusuke Tomoshige, Yugo Mishima, Tatsuya Niwa, Kenji Ohgane, Mayumi Ishii, Kayoko Kanamitsu, Yui Ikemi, Shinsaku Nakagawa, Hideki Taguchi, Shinichi Sato, Yuichi Hashimoto & Minoru Ishikawa
Similar books
- Long-Awaited Small-Molecule Drug Candidate for Drugging the Next Undruggable KRASG12D Mutant in Cancer Therapy — Robert B. Kargbo (2022)
- Small Molecule Inhibitors of KRAS G12C Mutant — Robert B. Kargbo (2021)
- Small-Molecule Inhibitor of the Oncogenic KRASG12C Mutant for the Treatment of Currently Incurable Cancer — Robert B. Kargbo (2022)
- Antitubercular Activity of Novel 2-(Quinoline-4-yloxy)acetamides with Improved Drug-Like Properties — Ana Flávia Borsoi, Laura Manzoli Alice, Nathalia Sperotto, Alessandro Silva Ramos, Bruno Lopes Abbadi, Fernanda Souza Macchi Hopf, Adilio da Silva Dadda, Raoní S. Rambo, Rodrigo Braccini Madeira Silva, Josiane Delgado Paz, Kenia Pissinate, Mauro Neves... (2022)
- Discovery of Phospholipase D Inhibitors with Improved Drug-like Properties and Central Nervous System Penetrance — Tricia L. May-Dracka, Fang Gao, Brian T. Hopkins, Xiaoping Hronowski, TeYu Chen, Jayanth V. Chodaparambil, Claire M. Metrick, Mike Cullivan, Istvan Enyedy, Maciej Kaliszczak, Mark W. Kankel, Isaac Marx, Mackenzie A. Michell-Robinson, Param Murugan, P.... (2022)
- Small Molecule Inhibitors of KRAS Mutant as a Therapeutic Strategy for the Treatment of Cancer — Robert B. Kargbo (2021)